US 9,851,354 B2 · Methods of treating fragile X syndrome and related disorders

Abstract

The present invention provides methods of alleviating a sign or a symptom of Fragile X Syndrome and relates disorders such as autism spectrum disorders.

Claims8

Dependent claims

A method of treating or alleviating a symptom of Fragile X Syndrome in a subject who has Fragile X Syndrome, comprising administering to the subject a composition comprising metadoxine.

Dependencies are inferred from the claim text.

Facts

Application

14/917,169Filed 9 Sep 2014 · continuation

Priority

9 Sep 2013

Published

US 2016/0193199 A17 Jul 2016

Granted

26 Dec 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

G01N 33/573
Immunoassay; Biospecific binding assay; Materials therefor: for enzymes or isoenzymes
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 31/4015
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: having oxo groups…
A61K 31/4425
Non condensed pyridines; Hydrogenated derivatives thereof: pyridinium derivatives, e.g. pralidoxime, pyridostigmine

Family

Application61/875,384Us provisional application · filed 9 Sep 2013

Application14/038,258Parent of this continuation · filed 26 Sep 2013

Application61/991,351Us provisional application · filed 9 May 2014

US 2016/0193199 A1Pre-grant publication · published 7 Jul 2016

US 2015/0073023 A1Published application

US 9,851,354 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

The present invention provides methods of alleviating a sign or a symptom of Fragile X Syndrome and relates disorders such as autism spectrum disorders.

Facts

Application

14/917,169Filed 9 Sep 2014 · continuation

Priority

9 Sep 2013

Published

US 2016/0193199 A17 Jul 2016

Granted

26 Dec 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

G01N 33/573
Immunoassay; Biospecific binding assay; Materials therefor: for enzymes or isoenzymes
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 31/4015
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: having oxo groups…
A61K 31/4425
Non condensed pyridines; Hydrogenated derivatives thereof: pyridinium derivatives, e.g. pralidoxime, pyridostigmine

Family

Application61/875,384Us provisional application · filed 9 Sep 2013

Application14/038,258Parent of this continuation · filed 26 Sep 2013

Application61/991,351Us provisional application · filed 9 May 2014

US 2016/0193199 A1Pre-grant publication · published 7 Jul 2016

US 2015/0073023 A1Published application

US 9,851,354 B2This patent

From the US filing history. Foreign family members aren’t listed.

Methods of treating fragile X syndrome and related disorders

Life of this patent

Abstract

Claims8

Methods of treating fragile X syndrome and related disorders

Life of this patent

Abstract

Claims8